MicroRNA expression signatures of stage, grade, and progression in clear cell RCC

Cancer Biology and Therapy

Volumn 15, Issue 3, 2014, Pages 329-341

  Gowrishankar, Banumathy ^a   Ibragimova, Ilsiya ^a   Zhou, Yan ^a   Slifker, Michael J ^a   Devarajan, Karthik ^a   Al Saleem, Tahseen ^a   Uzzo, Robert G ^a   Cairns, Paul ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Clear cell RCC; Expression; Grade; MicroRNA; MiRNA; Progression; RCC; Signatures; Stage

Indexed keywords

MICRORNA; MICRORNA 142 3P; MICRORNA 15 3P; MICRORNA 204 5P; MICRORNA 21 5P; MICRORNA 223 3P; MICRORNA 30A 5P; MICRORNA 31 5P; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CELL METABOLISM; DISEASE SEVERITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MIDDLE AGED; PATHOGENESIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VERY ELDERLY; DISEASE COURSE; GENETICS; KIDNEY TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896503813     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.27314     Document Type: Article

References (53)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30; PMID:23335087; http://dx.doi.org/10.3322/caac.21166
2. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of nonclear-cell histology. J Clin Oncol 2002; 20:2376-81; PMID:11981011; http://dx.doi.org/10.1200/JCO.2002.11.123 (Pubitemid 34441667)
3. Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol Ther 2010; 10:658-64; PMID:20814228; http://dx.doi.org/10.4161/cbt.10.7. 13247
4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67; PMID:2188735; http://dx.doi.org/10.1016/0092-8674(90) 90186-I
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70; PMID:10647931; http://dx.doi.org/10.1016/S0092-8674(00)81683-9 (Pubitemid 30046295)
6. Cairns P. Renal cell carcinoma. Cancer Biomark 2010; 9:461-73; PMID:22112490
7. Lam JS, Klatte T, Kim HL, Patard JJ, Breda A, Zisman A, Pantuck AJ, Figlin RA. Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol 2008; 65:235-62; PMID:17931881; http://dx.doi.org/10.1016/j. critrevonc.2007.08.003 (Pubitemid 351174051)
8. Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013; 14:159-67; PMID:23333114; http://dx.doi.org/10.1016/S1470-2045(12)70584-3
9. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19:92-105; PMID:18955434; http://dx.doi.org/10.1101/gr.082701.108
10. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-66; PMID:17060945; http://dx.doi.org/10.1038/nrc1997 (Pubitemid 44629897)
11. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-69; PMID:16557279; http://dx.doi.org/10.1038/nrc1840
12. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33:e179; PMID:16314309; http://dx.doi.org/10.1093/nar/gni178
13. Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer 2008; 113:450-60; PMID:18523999; http://dx.doi.org/10.1002/cncr.23566
14. Atlas CG; Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499:43-9; PMID:23792563; http://dx.doi.org/10.1038/nature12222
15. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009; 69:4674-81; PMID:19470766; http://dx.doi.org/10.1158/0008-5472.CAN-09-0146
16. Faragalla H, Youssef YM, Scorilas A, Khalil B, White NM, Mejia-Guerrero S, Khella H, Jewett MA, Evans A, Lichner Z, et al. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn 2012; 14:385-92; PMID:22580180; http://dx.doi.org/10.1016/j. jmoldx.2012.02.003
17. Spizzo R, Nicoloso MS, Croce CM, Calin GA. Snap Shot: MicroRNAs in Cancer. Cell 2009; 137:586-e1; PMID:19410551; http://dx.doi.org/10.1016/j.cell. 2009.04.040
18. Talotta F, Cimmino A, Matarazzo MR, Casalino L, De Vita G, D'Esposito M, Di Lauro R, Verde P. An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene 2009; 28:73-84; PMID:18850008; http://dx.doi.org/10.1038/onc.2008.370
19. Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 2008; 68:8164-72; PMID:18829576; http://dx.doi.org/10.1158/0008-5472.CAN-08-1305
20. Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, Hanahan D. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 2009; 23:2152-65; PMID:19759263; http://dx.doi.org/10.1101/gad.1820109
21. Juan D, Alexe G, Antes T, Liu H, Madabhushi A, Delisi C, Ganesan S, Bhanot G, Liou LS. Identification of a microRNA panel for clear-cell kidney cancer. Urology 2010; 75:835-41; PMID:20035975; http://dx.doi.org/10.1016/j. urology.2009.10.033
22. Osanto S, Qin Y, Buermans HP, Berkers J, Lerut E, Goeman JJ, van Poppel H. Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS One 2012; 7:e38298; PMID:22745662; http://dx.doi.org/10.1371/journal.pone.0038298
23. Lv M, Zhang X, Jia H, Li D, Zhang B, Zhang H, Hong M, Jiang T, Jiang Q, Lu J, et al. An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-α and cAMP/PKA pathways. Leukemia 2012; 26:769-77; PMID:21979877; http://dx.doi.org/10.1038/ leu.2011.273
24. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, Chandrashekhar YS, Hall JL, Roy S, Zeng Y, et al. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis. J Clin Invest 2010; 120:4141-54; PMID:20972335; http://dx.doi.org/10.1172/JCI42980
25. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 2010; 17:F19-36; PMID:19779035; http://dx.doi.org/10.1677/ERC-09-0184
26. Lujambio A, Lowe SW. The microcosmos of cancer. Nature 2012; 482:347-55; PMID:22337054; http://dx.doi.org/10.1038/nature10888
27. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 2007; 101:59-68; PMID:17540974; http://dx.doi.org/10.1161/CIRCRESAHA.107.153916 (Pubitemid 47094624)
28. Wang H, Ach RA, Curry B. Direct and sensitive miRNA profiling from low-input total RNA. RNA 2007; 13:151-9; PMID:17105992; http://dx.doi.org/10. 1261/rna.234507 (Pubitemid 46026189)
29. Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T, Pilarsky C, Johannsen M, Stephan C, Lehrach H, et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 2009; 13(9B):3918-28; PMID:19228262; http://dx.doi.org/10.1111/j. 1582-4934.2009.00705.x
30. Mikhaylova O, Stratton Y, Hall D, Kellner E, Ehmer B, Drew AF, Gallo CA, Plas DR, Biesiada J, Meller J, et al. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell 2012; 21:532-46; PMID:22516261; http://dx.doi.org/10. 1016/j.ccr.2012.02.019
31. Ying Z, Li Y, Wu J, Zhu X, Yang Y, Tian H, Li W, Hu B, Cheng SY, Li M. Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype. Cancer Res 2013; 73:990-9; PMID:23204229; http://dx.doi.org/10.1158/ 0008-5472.CAN-12-2895
32. Zou C, Xu Q, Mao F, Li D, Bian C, Liu LZ, Jiang Y, Chen X, Qi Y, Zhang X, et al. MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle 2012; 11:2137-45; PMID:22592534; http://dx.doi.org/10.4161/cc.20598
33. Slaby O, Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, Svoboda M, Vyzula R. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer 2012; 51:707-16; PMID:22492545; http://dx.doi.org/10.1002/gcc.21957
34. Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, Papotti M, Allgayer H. MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer 2012; 130:2044-53; PMID:21633953; http://dx.doi.org/10. 1002/ijc.26218
35. Sun L, Xie H, Mori MA, Alexander R, Yuan B, Hattangadi SM, Liu Q, Kahn CR, Lodish HF. Mir193b-365 is essential for brown fat differentiation. Nat Cell Biol 2011; 13:958-65; PMID:21743466; http://dx.doi.org/10.1038/ncb2286
36. Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, Evans C, Jensen RV, Moskaluk CA, Dutta A. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 2011; 71:1313-24; PMID:21212412; http://dx.doi.org/10.1158/0008-5472.CAN-10-1031
37. Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD, Prionidis K, Dalamagas T, Hatzigeorgiou AG. DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res 2012; 40:W498-504; PMID:22649059; http://dx.doi.org/10.1093/ nar/gks494
38. Weng L, Wu X, Gao H, Mu B, Li X, Wang JH, Guo C, Jin JM, Chen Z, Covarrubias M, et al. MicroRNA profiling of clear cell renal cell carcinoma by wholegenome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J Pathol 2010; 222:41-51; PMID:20593407
39. Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, Li Y, Nelson RA, Mu B, Onami SH, et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 2012; 7:e35661; PMID:22623952; http://dx.doi.org/10.1371/journal.pone.0035661
40. Liu Y, Lai L, Chen Q, Song Y, Xu S, Ma F, Wang X, Wang J, Yu H, Cao X, et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol 2012; 188:5500-10; PMID:22544933; http://dx.doi.org/10.4049/jimmunol.1103505
41. Huang S, Wang S, Bian C, Yang Z, Zhou H, Zeng Y, Li H, Han Q, Zhao RC. Upregulation of miR-22 promotes osteogenic differentiation and inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells by repressing HDAC6 protein expression. Stem Cells Dev 2012; 21:2531-40; PMID:22375943; http://dx.doi.org/10.1089/scd.2012.0014
42. Bar N, Dikstein R. miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PLoS One 2010; 5:e10859; PMID:20523723; http://dx.doi.org/10.1371/journal.pone.0010859
43. Yin G, Alvero AB, Craveiro V, Holmberg JC, Fu HH, Montagna MK, Yang Y, Chefetz-Menaker I, Nuti S, Rossi M, et al. Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene 2013; 32:39-49; PMID:22349827; http://dx.doi.org/10.1038/onc.2012.33
44. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida T, Sato F, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol 2008; 216:418-27; PMID:18925646; http://dx.doi.org/10.1002/ path.2437
45. White NM, Khella HW, Grigull J, Adzovic S, Youssef YM, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA, et al. miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer 2011; 105:1741-9; PMID:22033272; http://dx.doi.org/10.1038/bjc.2011.401
46. Morrogh M, Olvera N, Bogomolniy F, Borgen PI, King TA. Tissue preparation for laser capture microdissection and RNA extraction from fresh frozen breast tissue. Biotechniques 2007; 43:41-2, 44, 46 passim; PMID:17695251; http://dx.doi.org/10.2144/000112497
47. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol 2002; 167:57-60; PMID:11743275; http://dx.doi.org/10.1016/S0022-5347(05)65382-7 (Pubitemid 34024497)
48. Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Hadfield J, Bertone P, Caldas C. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 2010; 16:991-1006; PMID:20360395; http://dx.doi.org/10.1261/rna. 1947110
49. Pradervand S, Weber J, Lemoine F, Consales F, Paillusson A, Dupasquier M, Thomas J, Richter H, Kaessmann H, Beaudoing E, et al. Concordance among digital gene expression, microarrays, and qPCR when measuring differential expression of microRNAs. Biotechniques 2010; 48:219-22; PMID:20359303; http://dx.doi.org/ 10.2144/000113367
50. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655-63; PMID:7180965; http://dx.doi.org/10.1097/00000478-198210000-00007 (Pubitemid 13234762)
51. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A III. Chapter 43 Kidney. AJCC Cancer Staging Manual Seventh Edition 2009:479-90
52. Tissot C. Analysis of miRNA content in total RNA preparations using the Agilent 2100 bioanalyzer. Agilent Technologies Application Note 2008; Publication Number 5989-7870EN. Available from: http://www.chem.agilent.com/ Library/applications/5989-7870EN.pdf
53. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3:e3; PMID:16646809; http://dx.doi.org/10.2202/1544-6115.1027